Eli Lilly (LLY) Faces Delay for Orforglipron Approval Now Set for April 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: seekingalpha
- FDA Approval Delay: Eli Lilly's weight loss pill orforglipron now faces an FDA approval delay until April 2026, which is a setback from initial expectations and has led to a ~5% drop in stock price, marking its largest intraday loss in five months.
- Priority Review Program: The FDA's National Priority Review voucher program aims to expedite the review of experimental therapies from 10-12 months to just 1-2 months; however, delays faced by two recipients are impacting Lilly's drug approval timeline.
- Increased Market Competition: As Lilly's approval timeline extends, rival Novo Nordisk has launched its weight loss drug Wegovy in the U.S. at $149 per month, intensifying competition and potentially affecting Lilly's market share in the obesity drug sector.
- Executive Expectations Adjustment: While CEO David Ricks previously indicated that orforglipron could be approved as early as Q1 2026, CFO Lucas Montarce has tempered those expectations, now projecting a Q2 2026 approval, reflecting a cautious outlook on the drug's market entry prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1131.420
Low
950.00
Averages
1192
High
1500
Current: 1131.420
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
Foundayo Approved by FDA; Lilly to Seek Type 2 Diabetes Approval
- Clinical Trial Results: In three late-stage trials, Foundayo outperformed Novo Nordisk's semaglutide and AstraZeneca's dapagliflozin in blood sugar control and weight loss, with the 17.2 mg dose reducing blood sugar levels by 2.2 percentage points, demonstrating a statistically significant advantage.
- Market Expansion Potential: Lilly plans to submit Foundayo for U.S. regulatory approval for type 2 diabetes by the end of Q2, which is expected to expand the company's total addressable market by providing a convenient oral alternative for patients who prefer pills.
- Consistent Safety Data: Safety data across the three trials were consistent, with the most common side effects being mild-to-moderate gastrointestinal issues, and discontinuation rates remained in the low-to-mid teens, aligning with other oral GLP-1s.
- Positive Investor Sentiment: Lilly's shares closed about 2% higher on Monday and edged up after-hours, reflecting Wall Street's optimistic outlook on Foundayo as a potential first-line oral diabetes treatment, with the stock gaining approximately 49% over the past 12 months.
See More
Eli Lilly Acquires Three Biotech Firms for Infectious Disease Expansion
- Strategic Acquisition: Eli Lilly has announced the acquisition of three biotech firms—Curevo, LimmaTech, and Vaccine Company—at a total cost exceeding $3.8 billion, indicating a strong commitment to expanding its infectious disease prevention portfolio and future growth platforms.
- Vaccine Development Potential: Curevo's next-generation shingles vaccine has shown comparable immune response to GSK's Shingrix in phase 2 trials, and capturing just 10% of the market could yield approximately $480 million in annual sales, enhancing Lilly's competitive position in the vaccine market.
- Addressing Antibiotic Resistance: LimmaTech is developing vaccines against resistant bacterial pathogens, with significant market potential similar to Merck's Gardasil; successful vaccines could generate hundreds of millions to billions in annual revenue, aligning with the growing global health concerns.
- Future of Preventive Medicine: Lilly's acquisitions reflect a strategic shift towards preventive medicine, indicating the company is building a diversified therapeutic portfolio to address future market challenges and ensure sustained revenue growth beyond its current obesity-focused franchise.
See More
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
Foundayo Approved by FDA; Lilly to Seek Type 2 Diabetes Approval
- Clinical Trial Results: In three late-stage trials, Foundayo outperformed Novo Nordisk's semaglutide and AstraZeneca's dapagliflozin in blood sugar control and weight loss, with the 17.2 mg dose reducing blood sugar levels by 2.2 percentage points, demonstrating a statistically significant advantage.
- Market Expansion Potential: Lilly plans to submit Foundayo for U.S. regulatory approval for type 2 diabetes by the end of Q2, which is expected to expand the company's total addressable market by providing a convenient oral alternative for patients who prefer pills.
- Consistent Safety Data: Safety data across the three trials were consistent, with the most common side effects being mild-to-moderate gastrointestinal issues, and discontinuation rates remained in the low-to-mid teens, aligning with other oral GLP-1s.
- Positive Investor Sentiment: Lilly's shares closed about 2% higher on Monday and edged up after-hours, reflecting Wall Street's optimistic outlook on Foundayo as a potential first-line oral diabetes treatment, with the stock gaining approximately 49% over the past 12 months.
See More
Eli Lilly Acquires Three Biotech Firms for Infectious Disease Expansion
- Strategic Acquisition: Eli Lilly has announced the acquisition of three biotech firms—Curevo, LimmaTech, and Vaccine Company—at a total cost exceeding $3.8 billion, indicating a strong commitment to expanding its infectious disease prevention portfolio and future growth platforms.
- Vaccine Development Potential: Curevo's next-generation shingles vaccine has shown comparable immune response to GSK's Shingrix in phase 2 trials, and capturing just 10% of the market could yield approximately $480 million in annual sales, enhancing Lilly's competitive position in the vaccine market.
- Addressing Antibiotic Resistance: LimmaTech is developing vaccines against resistant bacterial pathogens, with significant market potential similar to Merck's Gardasil; successful vaccines could generate hundreds of millions to billions in annual revenue, aligning with the growing global health concerns.
- Future of Preventive Medicine: Lilly's acquisitions reflect a strategic shift towards preventive medicine, indicating the company is building a diversified therapeutic portfolio to address future market challenges and ensure sustained revenue growth beyond its current obesity-focused franchise.
See More
